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patients develop severe exocrine pancreatic insufficiency 
after pancreatoduodenectomy. The extent of exocrine pan-
creatic insufficiency is strongly correlated with preoperative 
fibrosis. The loss of endocrine tissue does not correlate with 
postoperative diabetes mellitus. Preoperative dilation of the 
pancreatic duct per se does not predict exocrine or endo-
crine pancreatic insufficiency postoperatively. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Both pylorus-preserving pancreatoduodenectomy and 
the classic Whipple resection are nowadays standard pro-
cedures for various benign and malignant diseases in the 
periampullary region. The morbidity, mortality and 
long-term survival after resection have been reported to 
be comparable for both procedures  [1–4] .
 Advances in operative techniques and improvements 
in perioperative management have led to an increasing 
number of long-term survivors after resection  [5] . There-
fore, their functional outcomes have attracted more at-
tention. Exocrine and endocrine pancreatic functions 
seem to be affected by factors such as the type of pancre-
atoenterostomy, the preoperative condition of the pan-
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 Abstract 
 Background: Obstruction of the pancreatic duct can lead to 
pancreatic fibrosis. We investigated the correlation between 
the extent of pancreatic fibrosis and the postoperative exo-
crine and endocrine pancreatic function.  Methods: Fifty-five 
patients who were treated for pancreatic and periampullary 
carcinoma and 19 patients with chronic pancreatitis were 
evaluated. Exocrine pancreatic function was evaluated by fe-
cal elastase-1 test, while endocrine pancreatic function was 
assessed by plasma glucose level. The extent of fibrosis, duct 
dilation and endocrine tissue loss was examined histopatho-
logically.  Results: A strong correlation was found between 
pancreatic fibrosis and elastase-1 level less than 100   g/g
(p  ! 0.0001), reflecting severe exocrine pancreatic insuffi-
ciency. A strong correlation was found between pancreatic 
fibrosis and endocrine tissue loss (p  ! 0.0001). Neither pan-
creatic fibrosis nor endocrine tissue loss were correlated 
with the development of postoperative diabetes mellitus. 
Duct dilation alone was neither correlated with exocrine nor 
with endocrine function loss.  Conclusion: The majority of 
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creas and the volume of the resected pancreas. However, 
the real pathogenesis behind pancreatic function loss re-
mains unclear. From a clinical point of view, the late post-
operative period is frequently characterized by various 
gastrointestinal problems, such as weight loss, malab-
sorption of essential nutrients (for example, fat-soluble 
vitamins) and steatorrhea, due to malfunctioning of the 
pancreatic remnant. Furthermore, we observed an inter-
esting fact that even in patients with a relatively normal 
pancreatic remnant, exocrine insufficiency occurs at the 
time of operation. Moreover, a substantial part of the pa-
tients develop diabetes mellitus after pancreatoduode-
nectomy. Fibrosis of the parenchyma of the pancreas has 
never been investigated before as a factor contributing to 
the malfunction of the pancreatic remnant.
 Therefore, we hypothesized that fibrosis of the pancre-
atic remnant secondary to chronic pancreatic duct ob-
struction might contribute to these functional changes of 
the pancreas.
 The aim of this study was to assess the correlation be-
tween the preoperative changes of the pancreas paren-
chyma (as reflected by the dilation of the pancreatic duct 
and the extent of fibrosis at the plane of transection) and 
the postoperative exocrine and endocrine function at 
least 6 months after pancreatoduodenectomy.
 Patients and Methods 
 Clinical Characteristics 
 In 2006, a nonconsecutive series of 55 patients, who had un-
dergone pancreatoduodenectomy for either pancreatic or periam-
pullary cancer at the Erasmus Medical Center in Rotterdam (The 
Netherlands) between 2001 and 2005, were evaluated for this clin-
ical study. Thirty-two patients had been treated for pancreatic 
cancer and 23  for periampullary cancer. Periampullary cancer 
was defined as cancer of the papilla vateri, distal bile duct cancer 
or periampullary duodenal cancer; pancreatic cancer was defined 
as cancer elsewhere in the pancreatic parenchyma. In addition, 19 
patients with chronic pancreatitis who underwent pancreatoduo-
denectomy during the same period were studied.
 Patients were evaluated in the outpatient clinic, where they 
were seen as a consecutive group for follow-up. Patients had to be 
at least 6 months after operation without signs of tumor recur-
rence and their resection specimen had to be available for careful 
examination.
 There were 45 men and 29 women. The mean age of these pa-
tients was 58.5 years (range 20–83).
 Surgery 
 After exclusion of distant metastasis and local irresectability, 
all patients underwent pancreatoduodenectomy. Twenty-six pa-
tients had a classical Kausch-Whipple resection, whereas 48 pa-
tients underwent pylorus-preserving pancreatoduodenectomy. 
End-to-side double-layer duct-to-mucosa pancreatojejunostomy 
was made according to the technique described by Cattell  [6] . 
Subsequently, single-layer end-to-side hepaticojejunostomy was 
performed. Finally antecolic end-to-side anastomosis was made 
between either the proximal duodenum or the gastric remnant 
and the proximal jejunum.
 Exocrine Function Assessment 
 To assess exocrine pancreatic function, the fecal elastase-1 test 
was used. Two feces samples were collected from each patient at 
least 6 months postoperatively. In 20 patients, preoperative elas-
tase-1 concentration was also available. The elastase-1 concentra-
tion was measured with a commercially available ELISA kit 
 (Schebo Biotech AG, Giessen, Germany). Enzyme replacement 
therapy was continued during the test period, since this does not 
affect the test results  [7] .
 Pancreatic function was considered normal when fecal elas-
tase-1 concentration exceeded 200   g/g feces, moderately insuf-
ficient when fecal elastase-1 concentration was between 100 and 
200   g/g feces and severely insufficient when elastase-1 concen-
tration was less than 100   g/g feces.
 Endocrine Function Assessment 
 Before surgery, apart from a casual glucose and hemoglobin 
glucose level determination, patients were asked whether they 
suffered from diabetes mellitus, polydipsia or polyuria and 
whether they used insulin or oral antidiabetic medication. Dur-
ing follow-up, casual glucose levels were measured frequently and 
patients were asked the same questions.
 Histology 
 The use of a semiquantitative method (the subjective quanti-
fication of an experienced individual pathologist) in the assess-
ment of histological changes of parenchyma, such as fibrosis, is 
considered accurate.
 In order to score the atrophy of the pancreas, an experienced 
gastrointestinal pathologist (H.v.D.) examined the plane of resec-
tion through the pancreas. Serial cross-sections of the plane of 
resection were fixed in 20% neutral phosphate-buffered formalin 
for light microscopy. Paraffin sections were stained with hema-
toxylin and eosin. The extent of fibrosis and remaining func-
tional exocrine tissue were assessed using a semiquantitative 
measurement method with 20-fold enlargement for light micros-
copy. Abnormalities were classified as mild or not affected if less 
than 25% fibrosis was observed, moderate if there was 25–75% 
and severe if more than 75% fibrosis was present ( fig. 1 ). Further-
more, the extent of dilation of the pancreatic duct was assessed. 
Dilation was defined as a duct diameter of more than 2 mm. In 
patients with missing histological duct samples, operation re-
ports and radiological data were screened for signs of duct dila-
tion.
 Endocrine tissue loss was determined in the plane of resection 
through the pancreas. Because of the more spread distribution of 
islands of Langerhans in the pancreatic corpus/tail, the presence 
of endocrine tissue was scored in only 2 categories semiquantita-
tively, that is, as mild when the estimated loss of endocrine tissue 
in the parenchyma was less than 50% compared with a normal 
pancreas parenchyma or as severe when the estimated loss of en-
docrine tissue was more than 50%.
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 Statistics 
 Data were analyzed using SPSS  version 11.0 (SPSS Inc., Chi-
cago, Ill., USA). The Mann-Whitney U test was performed for as-
sessing the study population means. Spearman’s rank test was 
used to determine correlations. The one-way ANOVA test was 
used to compare means of different groups, post hoc tested with 
the Bonferroni test. Test results were considered to denote statis-
tical significance if p  ! 0.05.
 Results 
 Elastase-1 
 Of the 74 patients, 56 (76%) showed fecal elastase-1 
levels less than 100   g/g, indicating severe pancreatic in-
sufficiency. Nine patients had elastase-1 levels between 
100 and 200   g/g, indicating mild insufficiency, and only 
9 patients had elastase levels above 200   g/g, which indi-
cates a normally functioning remnant.
 There was no significant difference in distribution of 
exocrine insufficiency in the 3 distinct groups as identi-
fied by underlying disease: severe insufficiency was found 
in 28/32 patients (88%) with pancreatic cancer, in 13/23 
patients (57%) with periampullary cancer and in 15/19 
patients (79%) with chronic pancreatitis.
 In the 20 patients in whom both pre- and postopera-
tive elastase-1 levels were available, there was a signifi-
cant decline postoperatively (p  ! 0.02;  fig. 2 ).
a b
c d
 Fig. 1. Histopathological classification of pancreatic fibrosis.  a Normal pancreatic parenchyma with normal 
distribution of exocrine and endocrine tissue (arrow indicates Langerhans islet).  b Mild fibrosis.  c Moderate 
fibrosis.  d Severe fibrosis (arrow indicates Langerhans islet). 
 Tran et al. Dig Surg 2008;25:311–318314
 Fibrosis 
 In 7 patients, no histological examination could be 
performed because of missing samples. Of the remaining 
67 patients, 33 had mild, 15 moderate and 19 severe fibro-
sis. The distribution of the extent of fibrosis between the 
groups with different underlying disease is shown in  ta-
ble 1 ; there was no significant difference between the 
groups (p = 0.08). A strong inverse correlation was ob-
served between the extent of fibrosis and the level of elas-
tase-1 in the fecal samples, both reflecting exocrine tissue 
loss (p  ! 0.0001;  fig. 3 ). 
 Duct Dilation 
 In 2 patients, no data could be retrieved to assess pan-
creatic duct diameter. The extent of pancreatic duct dila-
tion in the groups with different underlying diseases is 
outlined in  table 1 ; no significant difference was found 
between the 3 groups (p = 0.162). There was no (inversed) 
correlation between a dilated pancreatic duct and elas-
tase-1 levels in the feces (p = 0.599) or extent of fibrosis 
in the resection plane (p = 0.464).
 Endocrine Tissue 
 The loss of endocrine tissue in the resection plane 
could not be assessed in 7 patients because of missing 
samples. The results of endocrine tissue assessment are 
shown in  table 1 . Again, there were no significant differ-
ences between the groups (p  ! 0.838). A strong correla-
tion existed between endocrine tissue loss and the extent 
of fibrosis (p  ! 0.0001). No correlation existed between 
endocrine tissue loss and pancreatic duct dilation (p = 
0.735).
 Diabetes Mellitus 
 There were no missing samples. Sixty-four patients did 
not have diabetes before the operation. Prior to surgery, 6 
patients were already diagnosed as having insulin-depen-
dent diabetes and 4 patients were on oral antidiabetic 
medication. Overall, 19 patients (26%) developed diabetes 
after the operation (13 insulin-dependent diabetes, 6 non-
insulin-dependent diabetes). Neither for pancreatic duct 
dilation (p = 0.543) nor for endocrine tissue loss (p = 0.521) 
could a correlation be identified with postoperative dia-
betes (with or without preoperative diabetes).
 Discussion 
 This study focuses on the postoperative pancreatic 
function and its relation with preoperative loss of exo-
crine and endocrine pancreatic tissue (fibrosis) and a di-
lated pancreatic duct. Pancreatic function can be altered 
during the course of chronic pancreatitis. The main rea-
sons for the development of insufficiency are fibrosis and 
loss of functional tissue. In pancreatic cancer, especially 
the periampullary cancers, the destruction by cancer tis-
sue can be comprehended, but the remaining tissue is 
supposed to be sufficient and normal.
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 Fig. 2. Preoperative and postoperative elastase-1 concentration in 
20 patients who underwent pancreatoduodenectomy. * p = 0.02. 
 Fig. 3. Inversed correlation between the extent of fibrosis and 
elastase-1 level. p ! 0.0001. 
 Pancreatic Fibrosis and Exocrine 
Pancreatic Insufficiency  
Dig Surg 2008;25:311–318 315
 The majority of patients showed postoperative fecal 
elastase-1 levels lower than 100   g/g, indicating severe 
exocrine pancreatic insufficiency. Pancreatoduodenecto-
my is associated with exocrine and endocrine alterations 
 [8–11] . During follow-up, patients frequently report diffi-
culties with food intake, periods of diarrhea, altered con-
sistency of feces, steatorrhea and symptoms of malabsorp-
tion and subsequent malnutrition  [12] . Huang et al.  [13] 
reported a prevalence of 47 and 59% for foul stool after 
pancreatoduodenectomy because of malignant or benign 
pathology respectively, as well as 41 and 39% diabetes, re-
spectively, in a population of 192 patients. In another 
study, exocrine insufficiency symptoms like gross steator-
rhea increased from 17% before to 43% after surgery  [14] .
 Exocrine insufficiency can be tested by direct or indi-
rect function tests. The direct tests are more time-con-
suming, more expensive and unpleasant for the patients. 
Indirect tests, such as the fecal elastase-1 test, measure 
the consequences of pancreatic insufficiency and are 
more widely available.
 The elastase-1 test was used because of the good results 
obtained in previous studies in assessing moderate to se-
vere exocrine dysfunction of the pancreas  [7, 15–20] . This 
test has several advantages. First of all, the enzyme is sta-
ble during intestinal transport, secondly, elastase is con-
centrated in the feces, and finally, the enzyme is easily 
detected by means of an ELISA test.
 Pancreatic atrophy and concomitant fibrosis are 
thought to be responsible for the loss of exocrine and en-
docrine function  [21] . Occlusion of the pancreatic duct by 
tumor, by chronic inflammation coexisting with tumor 
or merely by chronic pancreatitis, causes fibrosis of the 
parenchyma  [22–25] . In this study, a significant inversed 
correlation was found between the histopathological ex-
tent of fibrosis and the level of elastase-1 test in the feces.
 Tanaka et al.  [24] reported an improvement of exo-
crine pancreatic function after 1 year compared with the 
test results within 2 months postoperatively. We did not 
analyze this phenomenon, since we only investigated pa-
tients more than 6 months postoperatively. In contrast to 
Table 1. Distribution of histological and hormonal changes in patients with pancreatic carcinoma, periampul-
lary carcinoma and chronic pancreatitis
Fibrosis Unknown Mild
(<25%)
Moderate
(25–75%)
Severe
(>75%)
Total
Pancreatic carcinoma
Periampullary carcinoma
Chronic pancreatitis
3
4
0
12
15
6
5
4
6
12
0
7
32
23
19
Total 7 33 15 19 74
Pancreatic duct dilation Unknown        No duct dilation Duct dilation Total
Pancreatic carcinoma
Periampullary carcinoma
Chronic pancreatitis
0
1
1
       4
       4
       7
28
18
11
32
23
19
Total 2        15 57 74
Endocrine tissue
(% Langerhans islets)
Unknown        Low (0–50%) High (50–100%) Total
Pancreatic carcinoma
Periampullary carcinoma
Chronic pancreatitis
3
4
0
       14
       1
       9
15
18
10
32
23
19
Total 7        24 43 74
Diabetes mellitus None        Preoperative Postoperative Total
Pancreatic carcinoma
Periampullary carcinoma
Chronic pancreatitis
20
14
11
       5
       3
       2
7
6
6
32
23
19
Total 45        10 19 74
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data from the literature, no inversed correlation was 
found between a dilated pancreatic duct and postopera-
tive elastase-1 levels in the feces (p = 0.599). Dilation of 
the pancreatic duct was neither correlated with exocrine 
nor with endocrine tissue loss. Therefore, a dilated pan-
creatic duct may be a sign of serious disease, but not a 
parameter of tissue destruction. Sato et al.  [23] mentioned 
a short-term postoperative exocrine impairment in pa-
tients with a preoperatively dilated pancreatic duct. Inter-
estingly, a substantial number of patients in our study 
with a normal pancreatic duct at the time of operation 
and only mild fibrosis still developed a severe exocrine 
insufficiency postoperatively, which suggests an ongoing 
exocrine and endocrine tissue loss after pancreatoduode-
nectomy. Pancreatic atrophy, as assessed by subtracting 
the diameter of the pancreatic duct from the total gland 
thickness, has previously been shown to develop over 
time following pancreatoduodenectomy  [26] and to cor-
relate well with exocrine insufficiency. Partial or total ob-
struction of the anastomosis might explain this phenom-
enon in some of the patients. Even a duct-to-mucosa 
anastomosis (which we also performed in all patients) 
could not prevent the ongoing process of tissue destruc-
tion in that study. It has been suggested that a pancreato-
jejunostomy allows a better preservation of the pancre-
atic exocrine function than a pancreatogastrostomy, 
which may be explained at least partly by neutralization 
of pancreatic enzymatic secretions due to gastric acid.
 In our study, a strong correlation existed between en-
docrine tissue loss and the extent of fibrosis, but there was 
no correlation between endocrine tissue loss and pancre-
atic duct dilation. Strikingly, neither pancreatic duct dila-
tion nor endocrine tissue loss were correlated with post-
operative diabetes mellitus. Since pancreatic fibrosis and 
exocrine tissue loss were studied 6 months before the clin-
ical endocrine and exocrine study, the observation that 
endocrine tissue loss is not correlated with diabetes mel-
litus could be explained by the persistence of endocrine 
tissue loss after the operation. This could also explain the 
fact that not all patients known with diabetes mellitus af-
ter 6 months were diabetic directly postoperatively.
 In a recent review, 70% of patients with pancreatic car-
cinoma had an impaired glucose tolerance test or frank 
diabetes preoperatively  [27] . Some authors suggest that 
diabetes may be an early manifestation of pancreatic ma-
lignancies  [10, 28] . Jang et al.  [29] reported an onset of 
diabetes mellitus in 44% of patients after pancreatoduo-
denectomy with pancreatojejunostomy and even in 75%
after pancreatoduodenectomy with pancreatogastrosto-
my. Sakorafas et al.  [14] reported an increase in diabetes 
from 8% before to 48% after pancreatoduodenectomy for 
chronic pancreatitis.
 In pancreatic head resection, 30–50% of the pancre-
atic parenchyma is involved and thus some degree of pan-
creatic insufficiency is induced  [30, 31] . Taking into ac-
count that most of the Langerhans islets are located in the 
tail of the pancreas, which is left in situ during pancre-
atoduodenectomy  [26] , the frequent postoperative onset 
of diabetes is less easy to explain. It has been suggested 
that other mechanisms are involved, such as an ongoing 
atrophy of the pancreatic parenchyma with impairment 
of the function of the islets of Langerhans. The loss of in-
sulin-secreting capacity was clearly shown in experimen-
tal data with dogs after pancreatic duct obstruction  [25] . 
Clinical data from our group showed that iatrogenic pan-
creatic duct occlusion after pancreatoduodenectomy 
leads to a significantly higher risk of endocrine insuffi-
ciency  [32] .
 More than one quarter of the patients developed dia-
betes after the operation, while 1 of 7 had diabetes already 
preoperatively. The decline of glucose tolerance after 
pancreatoduodenectomy seems to be associated with a 
low reserve of endocrine function rather than with the 
choice of a specific anastomosis (pancreaticojejunostomy 
or pancreaticogastrostomy) with its related complica-
tions  [33] .
 Our study has several limitations. Since the study pop-
ulation consisted of a nonconsecutive series of patients 
who were enrolled over a relatively long study period, an 
unintended patient selection bias might have played a 
role. However, as with other studies of pancreatic cancer, 
many patients died before enrollment, developed recur-
rent disease or were lost to follow-up. As the aim of this 
study was to assess the correlation between the preopera-
tive changes of the pancreas parenchyma and the postop-
erative exocrine and endocrine function at least 6 months 
after pancreatoduodenectomy, we did not mean to mea-
sure the elastase-1 concentration preoperatively. The re-
sults of elastase-1 concentration were notably abnormal 
during the study period and for this reason we decided to 
measure the elastase-1 concentration also in the preop-
erative phase in order to compare. This could be obtained 
from a small number of patients (n = 20). Another criti-
cism might be the relatively small number of patients in 
this study, which induces the risk of type 2 statistical er-
rors. The study objectives were merely aimed at the clin-
ical signs and feasibility of quantification of a histological 
observation. Since the results were obvious, we concluded 
that it was not necessary to extend the number of pa-
tients.
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 Furthermore, a later time point would have given more 
information about the course of the exocrine and endo-
crine insufficiency. Because the long-term survivors after 
a pancreatoduodenectomy do not seem to improve over 
years, the quality of life aspects become more important 
and therefore improvements in the clinical conditions 
must be pursued.
 Finally, the semiquantitative histopathological analy-
sis might be a relatively inaccurate method to judge the 
loss of exocrine and endocrine tissue.
 In conclusion, after pancreatoduodenectomy, the ex-
tent of exocrine pancreatic insufficiency is strongly cor-
related with preoperative fibrosis reflecting the preopera-
tive loss of functional pancreatic tissue. However, the loss 
of endocrine tissue does not correlate with postoperative 
diabetes mellitus. Preoperative dilation of the pancreatic 
duct per se does not predict exocrine or endocrine pan-
creatic insufficiency postoperatively.
 The high frequency of both exocrine and endocrine 
insufficiency after pancreatoduodenectomy warrants 
careful enzymatic supplementation and hormonal regu-
lation during postoperative follow-up.
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